Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) measured by Guardant Reveal in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with long-term disease control on first-line trastuzumab-pertuzumab.


Por: Llombart-Cussac A, Fernandez-Murga L, Martinez E, Santaballa A, Bermejo B, Rodríguez-Lescure A, Iranzo V, de la Morena P, Iranzo-Barreira J, Cortes J, Riva F, García J, Dustin D, Vidal-Martinez J, Liébana S, Serrano-Garcia L, Cejalvo J

Publicada: 1 jun 2025
Resumen:

ISSN: 0732183X





Journal Of Clinical Oncology
Editorial
AMER SOC CLINICAL ONCOLOGY, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 43 Número: 16_SUPPL
Páginas:
WOS Id: 001512568600001

MÉTRICAS